Hypervision Surgical Raises GBP 17M Series A for AI-Powered Surgical Imaging

Funding Overview

Hypervision Surgical, a London-based medical AI company, raised £17 million ($21 million) in Series A funding to advance its AI-powered hyperspectral imaging technology for real-time surgical guidance. The investment will accelerate regulatory approvals and expand commercial deployments across UK and European hospitals.

This funding round was led by Venture Science with participation from Elbow River Capital, Ripple Capital, and existing investors. The round values the company at approximately £85 million post-money, reflecting significant confidence in the technology's commercial potential.

The funding will support continued clinical validation, regulatory submissions for both FDA and CE marking, and commercial expansion across key markets. The company has established partnerships with leading NHS Trusts and European hospitals for ongoing clinical validation.

The Challenge of Surgical Accuracy

Surgical decision-making often relies on real-time visual assessment by the operating surgeon. However, the human eye can only perceive a limited portion of the electromagnetic spectrum, missing critical information about tissue composition, blood supply, and cellular viability.

Tissues that appear visually similar may have very different characteristics—distinguishing between malignant and healthy tissue, identifying perfused versus ischemic tissue, or detecting margins of tumors during resection. These decisions profoundly impact patient outcomes but rely heavily on surgeon experience and judgment.

Current surgical imaging technologies provide limited functional information. White-light endoscopy and microscopy reveal mostly structural information, while advanced imaging modalities like fluorescence imaging require exogenous contrast agents and provide limited spectral information.

The inability to distinguish between healthy and diseased tissue in real-time contributes to positive margins in cancer surgery, leading to repeat surgeries, adjuvant therapies, and increased healthcare costs. Studies indicate that 20-30% of cancer surgeries result in positive margins requiring additional treatment.

Improving surgical accuracy represents a significant unmet clinical need with substantial impact on patient outcomes, healthcare costs, and surgical efficiency. The healthcare system increasingly demands objective, quantitative decision support tools.

Hyperspectral Imaging Technology

Hypervision's platform captures reflected light across a broad spectral range (400-1700nm), generating a unique "optical fingerprint" for each tissue type. This hyperspectral data is processed using proprietary machine learning algorithms trained on thousands of tissue samples to provide real-time diagnostic information.

The system integrates with standard surgical cameras and displays, allowing seamless integration into existing surgical workflows. Real-time processing enables decision support without disrupting surgical flow or extending operative time.

Key capabilities include non-contact imaging (no contrast agents required), real-time processing (sub-second analysis), broad tissue differentiation (multiple tissue types identified), and compatibility with existing surgical equipment including standard HD surgical cameras.

The underlying technology was developed through a decade of research at University College London, combining expertise in optical physics, computational spectroscopy, and surgical oncology. The team published foundational papers demonstrating the utility of hyperspectral imaging for surgical tissue assessment.

Key Applications

The technology addresses several high-value surgical applications:

• Cancer Margin Detection: Identifies malignant tissue boundaries during tumor resection, potentially reducing positive margin rates
• Vascular Assessment: Determines tissue perfusion and viability in real-time, critical for colorectal and reconstructive surgery
• Nerve Identification: Visualizes nerve structures to avoid inadvertent damage during complex surgeries
• Tissue Differentiation: Distinguishes between tumor types and tissue classifications, providing diagnostic information during resection
• Anastomotic Assessment: Evaluates surgical connections (anastomoses) for viability before closing

Clinical Validation

The company has demonstrated clinical utility across multiple surgical specialties through prospective clinical studies. In colorectal surgery, the system has shown ability to identify malignant margins with sensitivity exceeding 90% and specificity above 85%.

In breast cancer surgery, Hypervision has demonstrated significant improvement in margin assessment compared to standard visual inspection and frozen section analysis. Studies published in Annals of Surgical Oncology show agreement with final pathology exceeding 95%.

Current partnerships include NHS Trusts in London, Manchester, and Birmingham, as well as several leading European hospitals in Germany and France. These partnerships provide ongoing clinical validation and real-world evidence generation.

The company has completed over 2,000 patient imaging procedures across its partnership sites, building one of the largest hyperspectral surgical imaging datasets in the world.

Leadership

Founded by Bilal Hashimoto, Tom Sterling, and Jon Mullen, the team combines expertise in optical physics, machine learning, and surgical oncology. Bilal Hashimoto serves as CEO, bringing 15 years of medical device commercialization experience from previous roles at major medical technology companies.

Tom Sterling, PhD, serves as Chief Technology Officer, leading the technical team and algorithm development. His research background includes pioneering work in computational spectroscopy and medical imaging at Cambridge University.

The team has grown to 45 employees across engineering, clinical, and commercial functions. Key hires include former executives from Medtronic and Intuitive Surgical who bring extensive commercialization experience in surgical markets.

Funding Allocation

The £17 million Series A will support continued clinical validation, regulatory approvals (FDA 510(k) and CE marking), and commercial expansion. The company targets FDA clearance by 2027 and subsequent commercial launch in the US market.

Funding will also support expansion of manufacturing capabilities, development of next-generation hardware optimized for specific surgical applications, and establishment of commercial partnerships with major surgical robotics companies.

Business Model

Hypervision generates revenue through device sales and per-procedure licensing. The reusable imaging system is sold to hospitals as capital equipment, with consumable software licenses sold per surgical procedure. This recurring revenue model provides predictable income streams.

Average selling price for the imaging system is £80,000-£120,000 depending on configuration, with per-procedure fees of £50-£150 depending on surgical specialty. The company targets hospitals performing high volumes of oncologic surgery.

Market Opportunity

The surgical AI market is projected to reach $3.5 billion by 2030, driven by increasing emphasis on surgical accuracy and value-based care. Key growth drivers include rising healthcare costs requiring better outcomes, surgical oncology demand for margin assessment, and minimally invasive surgery expansion.

Surgical imaging represents a significant portion of this market, with hyperspectral imaging positioned as a premium segment. The total addressable market for surgical margin assessment alone exceeds $2 billion globally.

Related companies in surgical AI include Proscia, which is accelerating digital pathology with AI-powered image analysis, and infiniteMD, which provides AI-driven medical imaging platforms.

Competitive Landscape

Current competitors include traditional white-light imaging systems (dominant market share from major medical device companies), fluorescence imaging systems (growing segment from companies like Stryker and Medtronic), and emerging hyperspectral imaging approaches (Hypervision's category with several academic groups and early-stage companies).

Hypervision's advantage is broad spectral coverage without contrast agents, real-time processing, and extensive clinical validation. The company has established relationships with key opinion leaders in surgical oncology that provide competitive barriers to entry.

Looking Ahead

Hypervision is positioned to transform surgical decision-making through objective, real-time tissue assessment. Success depends on continued clinical validation showing improved patient outcomes and efficient regulatory approvals in key markets.

The team plans to expand into additional surgical specialties beyond current applications, including neurosurgery and orthopedic spine surgery. Integration with surgical robotics platforms represents a significant partnership opportunity.